CU20140103A7 - Compuestos de cromano sustituidos como modulares del receptor sensible al calcio - Google Patents
Compuestos de cromano sustituidos como modulares del receptor sensible al calcioInfo
- Publication number
- CU20140103A7 CU20140103A7 CU2014000103A CU20140103A CU20140103A7 CU 20140103 A7 CU20140103 A7 CU 20140103A7 CU 2014000103 A CU2014000103 A CU 2014000103A CU 20140103 A CU20140103 A CU 20140103A CU 20140103 A7 CU20140103 A7 CU 20140103A7
- Authority
- CU
- Cuba
- Prior art keywords
- modular
- calcium
- sensitive
- receptor
- casr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Abstract
La presente invención proporciona moduladores del receptor sensible al calcio (CaSR). En particular, los compuestos descritos en la presente son útiles para tratar, manejar y/o reducir la gravedad de enfermedades, trastornos, síndromes y/o afecciones asociados con la modulación de los receptores sensibles al calcio (CaSR). La invención también proporciona en la presente las composiciones farmacéuticas de los mismos y métodos para tratar, manejar y/o reducir la gravedad de enfermedades, trastornos, síndromes y/o afecciones asociados con la modulación de CaSR. La invención también se refiere a un proceso para la preparación de los compuestos de la invención. ESPACIO PARA FÓRMULA
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN178KO2012 | 2012-02-24 | ||
| IN1030KO2012 | 2012-09-07 | ||
| PCT/IB2013/051445 WO2013124828A1 (en) | 2012-02-24 | 2013-02-22 | Substituted chroman compounds as calcium sensing receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20140103A7 true CU20140103A7 (es) | 2015-01-29 |
| CU24325B1 CU24325B1 (es) | 2018-03-13 |
Family
ID=54261188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2014000103A CU24325B1 (es) | 2012-02-24 | 2013-02-22 | Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores |
Country Status (44)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2817299T3 (pl) * | 2012-02-24 | 2019-12-31 | Lupin Limited | Podstawione związki chromanowe jako modulatory receptorów wapniowych |
| JP2015528462A (ja) * | 2012-08-27 | 2015-09-28 | ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ | カルシウム感知受容体モジュレーターとしてのアリールアルキルアミン化合物 |
| TW201602062A (zh) | 2013-08-12 | 2016-01-16 | 魯賓有限公司 | 取代聯苯基化合物作為鈣敏感受體調節劑 |
| WO2015028938A1 (en) | 2013-08-28 | 2015-03-05 | Lupin Limited | Substituted naphthalene compounds as calcium sensing receptor modulators |
| WO2015162538A1 (en) | 2014-04-21 | 2015-10-29 | Lupin Limited | Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease |
| WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| MX2022006087A (es) | 2019-11-19 | 2022-08-11 | Lupin Ltd | Proceso de preparación de compuestos de cromano. |
| EP4081210B1 (en) * | 2019-12-27 | 2026-04-15 | Lupin Limited | Pharmaceutical composition of casr modulators and methods and uses thereof |
| HRP20251132T1 (hr) | 2020-01-17 | 2025-11-21 | Lupin Limited | Postupci, procesi i međuproizvodi za pripremu spojeva kromana |
| WO2025255092A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a chromene derivative tcr inhibitor and a tyk2 inhibitor |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0020018B1 (en) * | 1979-05-19 | 1983-06-01 | Beecham Group Plc | Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them |
| US5387587A (en) * | 1986-12-23 | 1995-02-07 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Chroman derivatives |
| US6133277A (en) | 1997-12-05 | 2000-10-17 | Janssen Pharmaceutica N.V. | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
| FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
| WO2004069793A2 (en) | 2003-01-28 | 2004-08-19 | Bristol-Myers Squibb Company | Novel 2-substituted cyclic amines as calcium sensing receptor modulators |
| EP1630157A4 (en) | 2003-05-28 | 2007-05-23 | Japan Tobacco Inc | ANTAGONIST OF CASR |
| US7585886B2 (en) | 2005-05-19 | 2009-09-08 | Astellas Pharma Inc. | Pyrrolidine derivative or salt thereof |
| TW200815388A (en) | 2006-04-18 | 2008-04-01 | Wyeth Corp | Chromane and chromene derivatives and uses thereof |
| EP2079739A2 (en) | 2006-10-04 | 2009-07-22 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| MX2009003981A (es) * | 2006-10-26 | 2009-04-27 | Amgen Inc | Agentes moduladores del receptor de calcio. |
| WO2008059854A1 (en) | 2006-11-16 | 2008-05-22 | Astellas Pharma Inc. | Piperidine derivatives or salts thereof |
| ES2476391T3 (es) * | 2007-10-15 | 2014-07-14 | Amgen Inc. | Agentes moduladores de receptor de calcio |
| JP2011504471A (ja) | 2007-11-23 | 2011-02-10 | レオ ファーマ アクティーゼルスカブ | 疾病処置用の新規環式炭化水素 |
| WO2010038895A1 (ja) | 2008-10-03 | 2010-04-08 | 味の素株式会社 | ＣａＳＲアゴニスト |
| WO2010042642A1 (en) | 2008-10-08 | 2010-04-15 | Amgen Inc. | Calcium receptor modulating agents |
| US8765676B2 (en) | 2009-05-27 | 2014-07-01 | Leo Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| WO2010150837A1 (ja) | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
| JP2014508103A (ja) | 2010-11-26 | 2014-04-03 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
| EP2643292A1 (en) | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| JP2014500882A (ja) | 2010-11-26 | 2014-01-16 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
| CA2828415A1 (en) | 2011-03-10 | 2012-09-13 | Lupin Limited | Substituted morpholines as modulators for the calcium sensing receptor |
| SG193331A1 (en) | 2011-03-18 | 2013-10-30 | Lupin Ltd | Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators |
| PL2817299T3 (pl) * | 2012-02-24 | 2019-12-31 | Lupin Limited | Podstawione związki chromanowe jako modulatory receptorów wapniowych |
-
2013
- 2013-02-22 PL PL13712928T patent/PL2817299T3/pl unknown
- 2013-02-22 MY MYPI2014702272A patent/MY171374A/en unknown
- 2013-02-22 SI SI201331561T patent/SI2817299T1/sl unknown
- 2013-02-22 JP JP2014558258A patent/JP6114316B2/ja active Active
- 2013-02-22 IN IN1672MUN2014 patent/IN2014MN01672A/en unknown
- 2013-02-22 BR BR112014021133-7A patent/BR112014021133B1/pt active IP Right Grant
- 2013-02-22 NZ NZ628627A patent/NZ628627A/en unknown
- 2013-02-22 AP AP2014007919A patent/AP2014007919A0/xx unknown
- 2013-02-22 PT PT13712928T patent/PT2817299T/pt unknown
- 2013-02-22 KR KR1020147025242A patent/KR102041154B1/ko active Active
- 2013-02-22 US US14/380,632 patent/US9163001B2/en active Active
- 2013-02-22 SM SM20190506T patent/SMT201900506T1/it unknown
- 2013-02-22 CA CA2864332A patent/CA2864332C/en active Active
- 2013-02-22 ES ES13712928T patent/ES2743492T3/es active Active
- 2013-02-22 GE GEAP201813579A patent/GEAP201813579A/en unknown
- 2013-02-22 HR HRP20191606 patent/HRP20191606T1/hr unknown
- 2013-02-22 EP EP13712928.4A patent/EP2817299B1/en active Active
- 2013-02-22 CU CUP2014000103A patent/CU24325B1/es unknown
- 2013-02-22 AU AU2013223715A patent/AU2013223715B2/en active Active
- 2013-02-22 PE PE2014001297A patent/PE20142281A1/es active IP Right Grant
- 2013-02-22 MX MX2014010139A patent/MX355670B/es active IP Right Grant
- 2013-02-22 WO PCT/IB2013/051445 patent/WO2013124828A1/en not_active Ceased
- 2013-02-22 LT LTEP13712928.4T patent/LT2817299T/lt unknown
- 2013-02-22 GE GEAP201313579A patent/GEP20186911B/en unknown
- 2013-02-22 UA UAA201410409A patent/UA112679C2/uk unknown
- 2013-02-22 CN CN201380021510.0A patent/CN104350047B/zh active Active
- 2013-02-22 HU HUE13712928A patent/HUE046172T2/hu unknown
- 2013-02-22 EA EA201491582A patent/EA026940B9/ru unknown
- 2013-02-22 DK DK13712928.4T patent/DK2817299T3/da active
- 2013-02-22 SG SG11201405117SA patent/SG11201405117SA/en unknown
- 2013-02-22 RS RSP20191101 patent/RS59172B1/sr unknown
- 2013-02-23 TW TW102106358A patent/TWI617549B/zh not_active IP Right Cessation
- 2013-02-25 AR ARP130100556A patent/AR090135A1/es active IP Right Grant
-
2014
- 2014-08-14 TN TNP2014000352A patent/TN2014000352A1/fr unknown
- 2014-08-15 ZA ZA2014/05990A patent/ZA201405990B/en unknown
- 2014-08-20 PH PH12014501891A patent/PH12014501891B1/en unknown
- 2014-08-20 CL CL2014002218A patent/CL2014002218A1/es unknown
- 2014-08-21 DO DO2014000193A patent/DOP2014000193A/es unknown
- 2014-08-21 IL IL234252A patent/IL234252A/en active IP Right Grant
- 2014-08-21 NI NI201400094A patent/NI201400094A/es unknown
- 2014-08-22 GT GT201400179A patent/GT201400179A/es unknown
- 2014-09-10 MA MA37344A patent/MA35937B1/fr unknown
- 2014-09-17 CR CR20140424A patent/CR20140424A/es unknown
- 2014-09-23 CO CO14210706A patent/CO7160018A2/es unknown
-
2015
- 2015-09-01 US US14/842,141 patent/US9598391B2/en active Active
-
2017
- 2017-01-26 US US15/416,684 patent/US9987249B2/en active Active
-
2019
- 2019-09-10 CY CY20191100947T patent/CY1122017T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20140103A7 (es) | Compuestos de cromano sustituidos como modulares del receptor sensible al calcio | |
| MX336549B (es) | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1. | |
| DOP2015000054A (es) | Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
| CL2017001984A1 (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014) | |
| GT201400102A (es) | 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
| UY33199A (es) | 5-alquinil-pirimidinas. | |
| MX2017014956A (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. | |
| DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| CO2017006174A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis | |
| UY32574A (es) | Antagonistas del receptor cxcr3 | |
| MX346143B (es) | Ligandos del receptor ep1. | |
| NI201500050A (es) | Benzamidas | |
| CR20140553A (es) | Compuestos de fenoxietil piperidina | |
| ECSP14002542A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
| MX2016010529A (es) | Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6). | |
| ECSP11011454A (es) | 5-alquinil-piridinas | |
| UY33230A (es) | Aminotiazolonas como moduladores del receptor alfa relacionados con estrógeno | |
| CR20160215A (es) | Espiro-oxazolonas | |
| IN2015MN00421A (es) | ||
| CR20150068A (es) | Ciclopentilpirazoles como bloqueadores del canal de calcio tipo n | |
| UY33214A (es) | Compuestos de aril-bencil-amina | |
| UY32718A (es) | Compuestos derivados de 1, 3, 4-tiadiazol, útiles como agonistas del receptor de esfingosina 1-fosfato | |
| CU20080116A7 (es) | 3-aminociclopentanocarboxamidas como muduladores de receptores de quimioquinas |